P087 Inhibition of pleural inflammation hampers with bleomycin-induced lung profibrotic toxicity.

Olivier Burgy (1) , Pierre-Simon Bellaye Bellaye (1) , Sebastien Causse (1) , Pierre-Marie Boutanquoi (1) , Guillaume Wettstein (1) , Guillaume Beltramo (2) , Philippe Camus (1) , Carmen Garrido (1) , Françoise Goirand (1) , Philippe Bonniaud (3)

1 LNC - Lipides - Nutrition - Cancer (U866)
2 Service des maladies respiratoires [CHU de Dijon]
3 Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon]

The clinical use of bleomycin is restrained because of its lung toxicity with pulmonary fibrosis being the most devastating form. Toxic and idiopathic pulmonary fibrosis (PF) start classically in the subpleural area. It is known that 1) pleural mesothelial cells (PMCs) acquire a TGF-beta1-induced myofibroblast phenotype and 2) inflammation plays a significant role in fibrogenesis. The role of mesothelial cells in PF and in bleomycin lung toxicity has still to be investigated. C57Bl/6 mice were intravenously injected with bleomycin or NaCl. Repeated intravenous bleomycin induces a peculiar lung fibrotic response with 1) an histological peripheral distribution, 2) a collagen accumulation in pleural and subpleural area, 3) an overexpression of MMP-2, -9, HSP27, all involved in PMCs transformation and 4) a migration of PMCs into the lung....

Mots clés: lung; bleomycin; pleural infections and inflammations; toxic effect

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie; Pneumologie et système respiratoire

Olivier Burgy, Pierre-Simon Bellaye Bellaye, Sebastien Causse, Pierre-Marie Boutanquoi, Guillaume Wettstein, et al.. P087 Inhibition of pleural inflammation hampers with bleomycin-induced lung profibrotic toxicity.. QJM: An International Journal of Medicine, 2016, 109 (suppl_1), pp.S51. ⟨10.1093/qjmed/hcw127.023⟩. ⟨hal-01512935⟩